Agonistas de GLP-1 más inhibidores de SGLT2. ¿Efectos cardioprotectores aditivos?

Pharmacology, Toxicology and Pharmaceutical Science

• Glucagon Like Peptide 1 Receptor Agonist 100%
• Sodium Glucose Cotransporter 2 Inhibitor 100%
• Diabetes Mellitus 66%
• Glucagon-Like Peptide-1 66%
• Maturity Onset Diabetes of the Young 66%
• Clinical Study 33%
• Prevalence 33%
• Receptor Agonist 33%
• Glucagon 33%

Biochemistry, Genetics and Molecular Biology

• Glucagon-Like Peptide-1 100%
• Agonist 100%
• Metabolic Regulation 66%
• Lipid Profile 33%
• Clinical Study 33%
• Embase 33%
• Prevalence 33%
• Blood Pressure 33%
• Receptor Agonists 33%
• Search Engine 33%
• Glucagon 33%